Skip to main content
SpringerLink
Log in

Risk Adapted Chemoprevention for Prostate Cancer: An Option?

  • Chapter
  • First Online:
Prostate Cancer Prevention

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 202))

Abstract

A high disease prevalence, the presentation in older age, a frequently slowly progressing course of disease, and high costs make diagnosis and therapy of prostate cancer a special challenge for urologists. Effective prevention of the disease may help to resolve some of the problems mentioned above. Two randomised, controlled studies prove that effective chemoprevention of prostate cancer is possible using 5-α reductase inhibitors (finasteride, dutasteride) (LoE 1) both in individuals at low and those at high risk developing prostate cancer. Furthermore, there is evidence that other compounds, e.g. selective estrogen receptor modulators (SERMs), non-steroidal anti-inflammatory drugs (NSAIDs) and statins might also be effective. This review investigates potential risks and benefits of chemoprevention including a consideration of health economic aspects. The authors conclude that chemoprevention in a high risk cohort using 5-α reductase inhibitors is a viable option and may even be cost effective. In consequence, the options of chemoprevention in prostate cancer should be further explored in an open and unbiased way.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29(10):1335–1341

    Article  PubMed  Google Scholar 

  • Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL (2010) Rittmaster RS; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202

    Article  CAS  PubMed  Google Scholar 

  • Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308

    Article  PubMed Central  Google Scholar 

  • Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295:306–313

    Article  CAS  PubMed  Google Scholar 

  • Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, Lenzi A, Giugliano D (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 36(2):132–139

    CAS  PubMed  Google Scholar 

  • Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS (2013) Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 16(3):254–259

    Google Scholar 

  • Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E (2010) Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol 28(10):1714–1720

    Article  PubMed  Google Scholar 

  • Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid H-P, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71

    Article  PubMed  Google Scholar 

  • Hsieh LJ, Carter HB, Landis PK, Tucker KL, Metter EJ, Newschaffer CJ, Platz EA (2003) Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 61:297–301

    Article  PubMed  Google Scholar 

  • Jafari S, Etminan M, Afshar K (2009) Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 3(4):323–330

    PubMed Central  PubMed  Google Scholar 

  • Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P (2009) American Society of Clinical Oncology Health Services Committee; American Urological Association Practice Guidelines Committee. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 27(9):1502–1516

    Article  CAS  PubMed  Google Scholar 

  • Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ (2011) What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 29:464–467

    Article  PubMed  Google Scholar 

  • Luboldt HJ, Altwein JE, Bichler KH, Czaja D, Hüsing J, Fornara P, Jöckel KH, Lübben G, Schalkhäuser K, Weissbach L, Wirth M, Rübben H (1999) Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project group for early detection DGU-BDU laboratory diagnosis professional circle. Urologe A 38(2):114–123

    Article  CAS  PubMed  Google Scholar 

  • Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7):1680–1691

    Article  CAS  PubMed  Google Scholar 

  • Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H (2005) Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102:14813–14818

    Article  CAS  PubMed  Google Scholar 

  • Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R (2012) Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 109(8):1162–1169

    Article  CAS  PubMed  Google Scholar 

  • Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, Patrick DL, Ware JE, Ganz PA, Shumaker SA, Lippman SM, Coltman CA (2007) Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial. J Natl Cancer Inst 99:1025–1035

    Article  PubMed  Google Scholar 

  • Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, Donovan JL, Hamdy FC, Martin RM, Neal DE (2009) Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int 104(11):1592–1598

    Article  PubMed  Google Scholar 

  • Moyad MA (2004a) Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Urol Oncol 22:466–471

    Article  CAS  Google Scholar 

  • Moyad MA (2004b) Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol Oncol 22:472–477

    Article  CAS  Google Scholar 

  • Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ (2011) Guidelines on the management of non-neurogenic male LUTS. EAU Guidelines

    Google Scholar 

  • Price D, Stein B, Goluboff E, Sieber P, Bostwick D, Barnette KG, Steiner MS (2006) Toremifene for the prevention of prostate cancer among 514 men with high-grade prostatic intraepithelial neoplasia (PIN): results of a double-blind, placebo-controlled phase IIB trial. J Urol 176:965–970

    Article  CAS  PubMed  Google Scholar 

  • Redman MW, Tangen CM, Goodman PJ, Parnes H, Ford LG, Scott Lucia M, Coltman CA, Thompson IM (2008) Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 1(3):174–181

    Article  CAS  Google Scholar 

  • Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2009) JUPITER study group. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2(6):616–623

    Google Scholar 

  • Roberts EG, Vona-Davis L, Riggs DR, Jackson BJ, Hohseni H, Kandzari SJ, McFadden DW (2004) COX-2 inhibition and cancer: experimental findings and clinical correlates. W V Med J 100:96–100

    PubMed  Google Scholar 

  • Sarvis JA, Thompson IM (2008) Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep 10(6):529–532

    Article  CAS  PubMed  Google Scholar 

  • Scardino P (2003) The prevention of prostate cancer—the dilemma continues. N Engl J Med 349:297–299

    Article  PubMed  Google Scholar 

  • Schmid H-P, Engeler DS, Theiler R (2012) Anti-inflammatory drugs and prostatic carcinoma: current state of evidence. Akt Urol 43:112–114

    Article  Google Scholar 

  • Schmitz-Dräger BJ, Lümmen G, Bismarck E, Fischer C (2012) die Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK). Prävention Urologischer Erkrankungen. Urologe A 51(5):727–736

    Google Scholar 

  • Solomon KR, Freeman MR (2011) The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am 38(3):243–259

    Article  PubMed Central  PubMed  Google Scholar 

  • Stephan C, Miller K, Jung K (2011) Is there an optimal prostate-specific antigen threshold for prostate biopsy? Expert Rev Anticancer Ther 11(8):1215–21

    Google Scholar 

  • Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M (2013) Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 31(5) :523–529

    Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  CAS  PubMed  Google Scholar 

  • Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 350(22):2239–2246

    Article  CAS  PubMed  Google Scholar 

  • Unger JM, Thompson IM, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA (2005) Estimated impact of the prostate cancer prevention trial on population mortality. Cancer 103:1375–1380

    Article  PubMed  Google Scholar 

  • van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C (2007) The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 23:2063–2070

    Article  PubMed  Google Scholar 

  • Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS (2008) Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev (2): CD007091

    Google Scholar 

  • Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS (2010) 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int 106(10):1444–1451

    Article  CAS  PubMed  Google Scholar 

  • Wirth M, Weißbach L, Albrecht C, Göckel-Beining B, Fröhner M, Hinkelbein W, Miller K, Rübben H, Stöckle M, Wenz F, Wiegel T, Wolff J, Wörmann B (Hrsg) (2011) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 2.0, Aktualisierung

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologie, Schön Klinik Nürnberg/Fürth, Urologie 24, c/o Europa-Allee 1, 90763, Fürth, Germany

    Bernd J. Schmitz-Dräger & Sevim Sahin

  2. Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Lange Gasse 20, 90403, Nürnberg, Germany

    Oliver Schöffski

  3. Department of Urology, Medical University of Vienna, 1090, Vienna, Austria

    Michael Marberger

  4. Urologische Klinik, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland

    Hans-Peter Schmid

Authors
  1. Bernd J. Schmitz-Dräger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Schöffski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Marberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sevim Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans-Peter Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd J. Schmitz-Dräger .

Editor information

Editors and Affiliations

  1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

    Jack Cuzick

  2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

    Mangesh A. Thorat

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schmitz-Dräger, B.J., Schöffski, O., Marberger, M., Sahin, S., Schmid, HP. (2014). Risk Adapted Chemoprevention for Prostate Cancer: An Option?. In: Cuzick, J., Thorat, M. (eds) Prostate Cancer Prevention. Recent Results in Cancer Research, vol 202. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45195-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45195-9_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45194-2

  • Online ISBN: 978-3-642-45195-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation